参考文献/References:
[1] ZEISER R. Advances in understanding the pathogenesis of graft-versus-host disease[J]. Br J Haematol, 2019 , 187(5):563-572.
[2] MALARD F, HUANG Xiaojun, SIM J P Y. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease[J]. Leukemia, 2020, 34(5): 1229-1240.
[3] ALADA? E, KELKITLI E, G?KER H. Acute graft-versus-host disease: a brief review [J]. Turkish Journal of Haematology, 2020, 37(1): 1-4.
[4] CUSTOVIC A, BELGRAVE D, LIN Lijing, et al. Cytokine responses to rhinovirus and development of asthma, allergic sensitization, and respiratory infections during childhood[J]. American Journal of Respiratory and Critical Care Medicine, 2018, 197(10): 1265-1274.
[5] KAMEDA M, OTSUKA M, CHIBA H, et al. CXCL9, CXCL10 and CXCL11 biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features[J]. PLoS One, 2020, 15(11): e0241719.
[6] KOPER O M, KAMI ? SKA J, SAWICKI K, et al. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration[J]. Advances in Clinical and Experimental Medicine, 2018, 27(6): 849-856.
[7] KARIN N. CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells, and beyond[J]. Frontiers in Immunology, 2020, 11: 976.
[8] LU Huili, LIU Hongyu, WANG Jiaxian, et al. The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution[J]. Journal of Cancer Research and Clinical Oncology, 2015, 141(6): 983-992.
[9] ZHAO Qihong, KIM T, PANG Jian, et al. A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines[J]. Journal of Leukocyte Biology, 2017, 102(5): 1271-1280.
[10] NAJJAR I, FAGARD R. STAT1 and pathogens, not a friendly relationship[J]. Biochimie, 2010, 92(5): 425-444.
[11] AU K K, LE PAGE C, REN Runhan, et al. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer[J]. The Journal of Pathology Clinical Research, 2016, 2(4): 259-270.
[12] ZHANG Fan, MEARS J R, SHAKIB L, et al. IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation[J]. Genome Medicine, 2021, 13(1): 64.
[13] SUZUKI T, MARUYAMA J, COOK R, et al. Auditory function analysis in immunodeficient STAT1 knock-out mice: Considerations for viral infection models[J]. Neuroscience Letters, 2021, 740: 135427.
[14] TOLOMEO M, CAVALLI A, CASCIO A. STAT1 and its crucial role in the control of viral infections [J]. International Journal of Molecular Sciences, 2022, 23(8):4095.
[15] SAYOC-BECERRA A, KRISHNAN M, FAN Shujun, et al. The JAK-inhibitor tofacitinib rescues human intestinal epithelial cells and colonoids from Cytokine-induced barrier dysfunction[J]. Inflammatory Bowel Diseases, 2020, 26(3): 407-422.
[16] KANG Yuhui, BISWAS A, fiELD M, et al. STAT1 signaling shields T cells from NK cell-mediated cytotoxicity[J]. Nature Communications, 2019, 10(1):912.
[17] DOLASIA K, BISHT M K, PRADHAN G, et al. TLRs/ NLRs: shaping the landscape of host immunity[J]. International Reviews of Immunology, 2018, 37(1): 3-19.
[18] EL-ASMI F, MCMANUS F P, BRANTIS-DE-CARVALHO C E, et al. Cross-talk between SUMOylation and ISGylation in response to interferon[J]. Cytokine, 2020, 129: 155025.
[19] YáNEZ D C, ROSS S,CROMPTON T. The IfiTM protein family in adaptive immunity[J]. Immunology, 2020, 159(4): 365-372.
[20] LUO Shuaihanian, WU Ruifang, LI Qianwen, et al. Epigenetic regulation of Ifi44L expression in monocytes affects the functions of monocyte-derived dendritic cells in systemic lupus erythematosus[J]. J Immunol Res, 2022, 2022: 4053038.
[21] ZENG Yong, ZHANG Zhe, CHEN Hongqiang, et al. Comprehensive analysis of immune implication and prognostic value of Ifi44L in non-small cell lung cancer[J]. Frontiers in Oncology, 2021, 11: 798425.
[22] DEDIEGO M L, MARTINEZ-SOBRIDO L, TOPHAM D J. Novel functions of Ifi44L as a feedback regulator of host antiviral responses[J]. Journal of Virology, 2019, 93(21): e01159-19.
[23] SCHOGGINS J W, WILSON S J, PANIS M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response[J]. Nature, 2011, 472(7344): 481-485.
相似文献/References:
[1]石换丽,董慧凤.MDS核型正常患者骨髓DNMT3A,FAT1和IL-7R基因突变对allo-HSCT治疗预后的影响[J].现代检验医学杂志,2025,40(05):82.[doi:10.3969/j.issn.1671-7414.2025.05.016]
SHI Huanli,DONG Huifeng.Impact of DNMT3A, FAT1, IL-7R Gene Mutations on the Prognosis of Allo-HSCT in MDS Patients with Normal Karyotype[J].Journal of Modern Laboratory Medicine,2025,40(02):82.[doi:10.3969/j.issn.1671-7414.2025.05.016]
[2]王红春,李 梦,孙文利,等.异基因造血干细胞移植患者伏立康唑血药浓度监测不达标风险预测模型建立及验证[J].现代检验医学杂志,2025,40(06):74.[doi:10.3969/j.issn.1671-7414.2025.06.014]
WANG Hongchun,LI Meng,SUN Wenli,et al.Development and Validation of a Nomogram Prediction Model for Subtherapeutic Voriconazole Concentrations in Allogeneic Hematopoietic Stem Cell Transplantation Recipients[J].Journal of Modern Laboratory Medicine,2025,40(02):74.[doi:10.3969/j.issn.1671-7414.2025.06.014]